66 related articles for article (PubMed ID: 19865110)
1. PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL.
Schachter-Tokarz E; Kelaidi C; Cassinat B; Chomienne C; Gardin C; Raffoux E; Dombret H; Fenaux P; Gallagher R
Leukemia; 2010 Feb; 24(2):473-6. PubMed ID: 19865110
[No Abstract] [Full Text] [Related]
2. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
[TBL] [Abstract][Full Text] [Related]
3. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
4. Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia?
Subramaniyam S; Nandula SV; Nichols G; Weiner M; Satwani P; Alobeid B; Bhagat G; Murty VV
Leukemia; 2006 Dec; 20(12):2193-5. PubMed ID: 17008891
[No Abstract] [Full Text] [Related]
5. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
Breccia M; Diverio D; Noguera NI; Visani G; Santoro A; Locatelli F; Damiani D; Marmont F; Vignetti M; Petti MC; Lo Coco F
Haematologica; 2004 Jan; 89(1):29-33. PubMed ID: 14754603
[TBL] [Abstract][Full Text] [Related]
6. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
Noguera NI; Breccia M; Divona M; Diverio D; Costa V; De Santis S; Avvisati G; Pinazzi MB; Petti MC; Mandelli F; Lo Coco F
Leukemia; 2002 Nov; 16(11):2185-9. PubMed ID: 12399960
[TBL] [Abstract][Full Text] [Related]
9. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
He LZ; Merghoub T; Pandolfi PP
Oncogene; 1999 Sep; 18(38):5278-92. PubMed ID: 10498880
[TBL] [Abstract][Full Text] [Related]
10. Identification of a point mutation PML
Zhao S; Shi P; Zhong Q; Shao S; Huang Y; Sun Y; Wu C; Zhu HH
Biochem Biophys Res Commun; 2019 Apr; 511(3):518-523. PubMed ID: 30824184
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
Ha JS; Do YR; Ki CS; Lee C; Kim DH; Lee W; Ryoo NH; Jeon DS
Leukemia; 2017 Sep; 31(9):1992-1995. PubMed ID: 28555082
[No Abstract] [Full Text] [Related]
12. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint.
Biondi A; Luciano A; Bassan R; Mininni D; Specchia G; Lanzi E; Castagna S; Cantù-Rajnoldi A; Liso V; Masera G
Leukemia; 1995 Sep; 9(9):1461-6. PubMed ID: 7658712
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
14. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
16. Cryptic t(15;17) acute promyelocytic leukemia with a karyotype of add(11)(p15) and t(13,20)- A case report with a literature review.
Gu S; Zi J; Ma J; Ge Z
Bosn J Basic Med Sci; 2021 Apr; 21(2):246-251. PubMed ID: 33052080
[TBL] [Abstract][Full Text] [Related]
17. Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
McMullin MF; Nugent E; Thompson A; Hull D; Jones FG; Grimwade D
Leukemia; 2005 Sep; 19(9):1676-7. PubMed ID: 16034463
[No Abstract] [Full Text] [Related]
18. Therapy-related myeloproliferative neoplasm with ETV6-PDGFRB rearrangement following treatment of acute promyelocytic leukemia.
Malfuson JV; Konopacki J; Fagot T; Desangles F; Bories D; Souleau B; de Revel T
Ann Hematol; 2011 Dec; 90(12):1477-9. PubMed ID: 21350831
[No Abstract] [Full Text] [Related]
19. Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Iaccarino L; Ottone T; Hasan SK; Divona M; Cicconi L; Lavorgna S; Alfonso V; Basso G; Barragán E; Bocchia M; Rego EM; Grimwade D; Voso MT; Lo-Coco F
Leuk Lymphoma; 2018 May; 59(5):1268-1270. PubMed ID: 28838264
[No Abstract] [Full Text] [Related]
20. Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy.
Breccia M; Stefania de Propris M; Molica M; Colafigli G; Minotti C; Diverio D; Latagliata R; Guarini A; Lo-Coco F; Foà R
Am J Hematol; 2015 Sep; 90(9):E181-2. PubMed ID: 26119985
[No Abstract] [Full Text] [Related]
[Next] [New Search]
